Please assess the completion status of the following clinical trial:

Trial Title: Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women over 18 years~* Free and informed consent signed~* Histologically confirmed adenocarcinoma of the breast, metastatic or non-metastatic~* LVEF\> 50% angioscintigraphy before the start of treatment with Herceptin ®,~* Overexpression of HER2 in the invasive component of the primary tumor (3 + 2 + according to ICH or with confirmation of positivity by FISH or CISH)~* Patient receiving treatment with Herceptin ®,~* Inclusion in the control group: patients treated with Herceptin ® episode without LV dysfunction,~* For the inclusion in the Group LV dysfunction: the appearance of a decrease in LVEF during treatment with Herceptin ®, angioscintigraphy identified.~Exclusion Criteria:~* Heart disease or serious medical conditions do not allow to administer Herceptin ® (documented history of heart failure, angina requiring treatment, severe dyspnoea at rest or oxygen dependency),~* History of ischemic heart disease or myocarditis~* Known allergy to trastuzumab, murine proteins or any of the excipients~* Patients with an indication against the MRI (claustrophobia, ferromagnetic foreign body, pacemaker or implantable defibrillator, known allergy to gadolinium salts)~* Renal impairment (creatinine clearance \<60 ml / min according to the MDRD formula)~* Arrhythmia atrial fibrillation,~* Contraindications to the administration of Dotarem ®,~* Patient unable to give informed consent,~* Adult Trust,~* Pregnant or lactating~* Patient unable to undergo a medical for geographical, social or psychological.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LV dysfunction group (Type: OTHER): Cardiac MRI
- Control group (Type: OTHER): Cardiac MRI

Based on this trial design, predict the completion outcome and termination type (if applicable).